SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-142019
Filing Date
2023-05-11
Accepted
2023-05-11 16:11:07
Documents
14
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d421860d8k.htm   iXBRL 8-K 25005
2 EX-99.1 d421860dex991.htm EX-99.1 52045
6 GRAPHIC g421860g0510033627861.jpg GRAPHIC 4863
  Complete submission text file 0001193125-23-142019.txt   213442

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA elvn-20230511.xsd EX-101.SCH 2839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20230511_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20230511_pre.xml EX-101.PRE 11251
8 EXTRACTED XBRL INSTANCE DOCUMENT d421860d8k_htm.xml XML 3345
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 23911109
SIC: 2834 Pharmaceutical Preparations